Patterns of Somatic Mutation in Human Cancer Genomes

Cancers arise owing to mutations in a subset of genes that confer growth advantage. The availability of the human genome sequence led us to propose that systematic resequencing of cancer genomes for mutations would lead to the discovery of many additional cancer genes. Here we report more than 1,000 somatic mutations found in 274 megabases (Mb) of DNA corresponding to the coding exons of 518 protein kinase genes in 210 diverse human cancers. There was substantial variation in the number and pattern of mutations in individual cancers reflecting different exposures, DNA repair defects and cellular origins. Most somatic mutations are likely to be 'passengers' that do not contribute to oncogenesis. However, there was evidence for 'driver' mutations contributing to the development of the cancers studied in approximately 120 genes. Systematic sequencing of cancer genomes therefore reveals the evolutionary diversity of cancers and implicates a larger repertoire of cancer genes than previously anticipated.

Citing Articles

Tumor-Agnostic Therapies in Practice: Challenges, Innovations, and Future Perspectives.

Wu S, Thawani R Cancers (Basel). 2025; 17(5).

PMID: 40075649 PMC: 11899253. DOI: 10.3390/cancers17050801.

Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection.

Bruhm D, Vulpescu N, Foda Z, Phallen J, Scharpf R, Velculescu V Nat Rev Cancer. 2025; .

PMID: 40038442 DOI: 10.1038/s41568-025-00795-x.

Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies.

Pouyan A, Ghorbanlo M, Eslami M, Jahanshahi M, Ziaei E, Salami A Mol Cancer. 2025; 24(1):58.

PMID: 40011944 PMC: 11863469. DOI: 10.1186/s12943-025-02267-0.

Identifying somatic driver mutations in cancer with a language model of the human genome.

Zeng G, Zhao C, Li G, Huang Z, Zhuang J, Liang X Comput Struct Biotechnol J. 2025; 27:531-540.

PMID: 39968174 PMC: 11833646. DOI: 10.1016/j.csbj.2025.01.011.

Attenuated titin protein expression is associated with advanced stages of ovarian cancer.

Sharma H, Aujla J, Nawaz A, Khasawneh T, Alvero A, Morris R Mol Ther Oncol. 2025; 33(1):200932.

PMID: 39944242 PMC: 11815674. DOI: 10.1016/j.omton.2025.200932.

References

Futreal P, Coin L, Marshall M, Down T, Hubbard T, Wooster R . A census of human cancer genes. Nat Rev Cancer. 2004; 4(3):177-83. PMC: 2665285. DOI: 10.1038/nrc1299. View

Karran P, Offman J, Bignami M . Human mismatch repair, drug-induced DNA damage, and secondary cancer. Biochimie. 2004; 85(11):1149-60. DOI: 10.1016/j.biochi.2003.10.007. View

Wan P, Garnett M, Roe S, Lee S, Niculescu-Duvaz D, Good V . Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004; 116(6):855-67. DOI: 10.1016/s0092-8674(04)00215-6. View

Goldman N, Yang Z . A codon-based model of nucleotide substitution for protein-coding DNA sequences. Mol Biol Evol. 1994; 11(5):725-36. DOI: 10.1093/oxfordjournals.molbev.a040153. View

Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J . Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995; 268(5215):1336-8. DOI: 10.1126/science.7761852. View

Teng D, Perry 3rd W, Hogan J, Baumgard M, Bell R, Berry S . Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res. 1997; 57(19):4177-82. View

Machado C, Sunkel C, ANDREW D . Human autoantibodies reveal titin as a chromosomal protein. J Cell Biol. 1998; 141(2):321-33. PMC: 2148454. DOI: 10.1083/jcb.141.2.321. View

Su G, Hilgers W, Shekher M, Tang D, Yeo C, Hruban R . Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res. 1998; 58(11):2339-42. View

Cappellen D, de Oliveira C, Ricol D, de Medina S, BOURDIN J, Sastre-Garau X . Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999; 23(1):18-20. DOI: 10.1038/12615. View

10.

Sawyers C . Targeted cancer therapy. Nature. 2004; 432(7015):294-7. DOI: 10.1038/nature03095. View

11.

Mi H, Lazareva-Ulitsky B, Loo R, Kejariwal A, Vandergriff J, Rabkin S . The PANTHER database of protein families, subfamilies, functions and pathways. Nucleic Acids Res. 2004; 33(Database issue):D284-8. PMC: 540032. DOI: 10.1093/nar/gki078. View

12.

Joshi-Tope G, Gillespie M, Vastrik I, DEustachio P, Schmidt E, de Bono B . Reactome: a knowledgebase of biological pathways. Nucleic Acids Res. 2004; 33(Database issue):D428-32. PMC: 540026. DOI: 10.1093/nar/gki072. View

13.

Lonardi S, Tosoni A, Brandes A . Adjuvant chemotherapy in the treatment of high grade gliomas. Cancer Treat Rev. 2005; 31(2):79-89. DOI: 10.1016/j.ctrv.2004.12.005. View

14.

Stephens P, Edkins S, Davies H, Greenman C, Cox C, Hunter C . A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet. 2005; 37(6):590-2. DOI: 10.1038/ng1571. View

15.

Parsons D, Wang T, Samuels Y, Bardelli A, Cummins J, Delong L . Colorectal cancer: mutations in a signalling pathway. Nature. 2005; 436(7052):792. DOI: 10.1038/436792a. View

16.

Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G . Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 2005; 65(17):7591-5. DOI: 10.1158/0008-5472.CAN-05-1855. View

17.

Granzier H, Labeit S . Titin and its associated proteins: the third myofilament system of the sarcomere. Adv Protein Chem. 2005; 71:89-119. DOI: 10.1016/S0065-3233(04)71003-7. View

18.

Bignell G, Smith R, Hunter C, Stephens P, Davies H, Greenman C . Sequence analysis of the protein kinase gene family in human testicular germ-cell tumors of adolescents and adults. Genes Chromosomes Cancer. 2005; 45(1):42-6. PMC: 7212027. DOI: 10.1002/gcc.20265. View

19.

Zastrow M, Flaherty D, Benian G, Wilson K . Nuclear titin interacts with A- and B-type lamins in vitro and in vivo. J Cell Sci. 2006; 119(Pt 2):239-49. DOI: 10.1242/jcs.02728. View

20.

Hunter C, Smith R, Cahill D, Stephens P, Stevens C, Teague J . A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 2006; 66(8):3987-91. PMC: 7212022. DOI: 10.1158/0008-5472.CAN-06-0127. View